Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 1, 2009Critical Pathways in Cardiology A Journal of Evidence-Based Medicine

Regional and Practice Variation in Adherence to Guideline Recommendations for Secondary and Primary Prevention Among Outpatients With Atherothrombosis or Risk Factors in the United States

View Full Paper
Ask AI
Bookmark
Share

Key result

Among 25,686 US outpatients with atherothrombosis or risk factors, only 65% with known disease received ≥3 of 4 major secondary prevention drug classes, varying by region and physician specialty.

Population

25,686 outpatients in the United States aged ≥45 years with either established atherothrombotic disease or…

Design

Cross-sectional

Authors

AKAmit KumarGFGregg C. FonarowKEKim A. Eagle

Discussion

Loading...

Member takes

Overview

Suboptimal secondary prevention adherence persists in US outpatients; leaves open how regional and specialty factors drive implementation gaps.

Study Design

Type

Observational (n=25,686)

Multicenter

Yes

Structured PICO

P
Population
25,686 outpatients aged ≥45 years with established atherothrombotic disease or ≥3 atherosclerosis risk factors in the United States.
E
Exposure
Guideline-recommended preventive therapies (antiplatelet agents, lipid-lowering agents, ACE inhibitors or ARBs, and beta-blockers)
O
Outcome
Adherence rates to guideline-recommended preventive therapies according to geographic region and treating physician specialty

Adherence to guideline-recommended preventive therapies in US outpatients varies significantly by geographic region and treating physician specialty, highlighting gaps in the implementation of evidence-based care.

Cite This Study

Kumar et al. (2009) conducted an observational in Atherothrombosis or risk factors (n=25,686). Geographic region and physician specialty was evaluated on Use of guideline-recommended preventive therapies. Among 25,686 US outpatients with atherothrombosis or risk factors, only 65% with known disease received ≥3 of 4 major secondary prevention drug classes, varying by region and physician specialty.

synapsesocial.com/papers/6a71c4e8439bab0cabc3aaf4https://doi.org/10.1097/hpc.0b013e3181b8395d
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update2002 · 1,860 citations
  2. 2Long-Term Adherence to Evidence-Based Secondary Prevention Therapies in Coronary Artery Disease2006 · 508 citations
  3. 3International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis2006 · 1,631 citations
  4. 4Primary Prevention of Ischemic Stroke2006 · 1,372 citations
  5. 5Aspirin for the Primary Prevention of Cardiovascular Events: A Summary of the Evidence for the U.S. Preventive Services Task Force2002 · 633 citations